Design of vaccine efficacy trials during public health emergencies-Reference-Cited by-同舟云学术

Design of vaccine efficacy trials during public health emergencies

Published:2019-07-03 Issue:499 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Dean Natalie E.¹,Gsell Pierre-Stéphane²,Brookmeyer Ron³^ORCID,De Gruttola Victor⁴,Donnelly Christl A.⁵⁶,Halloran M. Elizabeth⁷⁸^ORCID,Jasseh Momodou⁹,Nason Martha¹⁰^ORCID,Riveros Ximena²,Watson Conall H.¹¹^ORCID,Henao-Restrepo Ana Maria²,Longini Ira M.¹^ORCID

Affiliation:

1. Department of Biostatistics, University of Florida, Gainesville, FL, USA.

2. World Health Organization, Geneva, Switzerland.

3. Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, USA.

4. Department of Biostatistics, Harvard University, Boston, MA, USA.

5. Department of Statistics, University of Oxford, Oxford, UK.

6. MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.

7. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

8. Department of Biostatistics, University of Washington, Seattle, WA, USA.

9. Medical Research Council, The Gambia at London School of Hygiene and Tropical Medicine, Fajara, The Gambia.

10. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.

11. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Abstract

This Perspective describes key considerations for the design and analysis of candidate vaccine trials during public health emergencies.

Funder

National Institutes of Health

Medical Research Council

National Institute of Allergy and Infectious Diseases

National Institute for Health Research

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference40 articles.

1. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola

2. WHO R&D Blueprint: a global coordination mechanism for R&D preparedness

3. WHO R&D Blueprint: List of Blueprint priority diseases; www.who.int/blueprint/priority-diseases/en/.

4. Statistics and logistics: Design of Ebola vaccine trials in West Africa

5. National Academies of Sciences Engineering and Medicine Integrating Clinical Research into Epidemic Response: The Ebola Experience (National Academies Press 2017).

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two centuries of vaccination: historical and conceptual approach and future perspectives;Frontiers in Public Health;2024-01-09

2. A review on Zika vaccine development;Pathogens and Disease;2024

3. 4.1 In Practice: Vaccine Efficacy and Safety Testing—An Ethical Case for Individual Randomization;Principles and Practice of Emergency Research Response;2024

4. 22.1 In Focus: Ring Trial Design;Principles and Practice of Emergency Research Response;2024

5. 2 Clinical Research on Infectious Diseases: An Overview;Principles and Practice of Emergency Research Response;2024